Skip to content

Study · Randomized controlled trial · 1987

10 results

Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.

Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D

International journal of clinical pharmacology research1 Jan 1987Cited by 3 (Europe PMC)

PMID3583493 (opens in a new tab)PepBankPUB-03583493
Publisher pageAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, nocturnal awakenings were lower under DSIP but not significantly different from baseline or placebo nights.

    In plain wordsIn people with chronic insomnia, night waking was lower with DSIP, but not significantly different from baseline or placebo.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeNumber of nocturnal awakenings
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    The number of nocturnal awakenings, non-rapid-eye-movement (NREM) sleep latency, total waking time and waking time after sleep onset were decreased under DSIP treatment, but no significant differences were found in comparison to baseline or to double-blind placebo nights.
    1 context sentence
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, NREM sleep latency was lower under DSIP but not significantly different from baseline or placebo nights.

    In plain wordsIn people with chronic insomnia, time to fall into NREM sleep was shorter with DSIP, but not significantly different from baseline or placebo.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeNREM sleep latency
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    The number of nocturnal awakenings, non-rapid-eye-movement (NREM) sleep latency, total waking time and waking time after sleep onset were decreased under DSIP treatment, but no significant differences were found in comparison to baseline or to double-blind placebo nights.
    1 context sentence
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, total waking time was lower under DSIP but not significantly different from baseline or placebo nights.

    In plain wordsIn people with chronic insomnia, total time awake was lower with DSIP, but not significantly different from baseline or placebo.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeTotal waking time
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    The number of nocturnal awakenings, non-rapid-eye-movement (NREM) sleep latency, total waking time and waking time after sleep onset were decreased under DSIP treatment, but no significant differences were found in comparison to baseline or to double-blind placebo nights.
    1 context sentence
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, waking time after sleep onset was lower under DSIP but not significantly different from baseline or placebo nights.

    In plain wordsIn people with chronic insomnia, time awake after falling asleep was lower with DSIP, but not significantly different from baseline or placebo.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeWaking time after sleep onset
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    The number of nocturnal awakenings, non-rapid-eye-movement (NREM) sleep latency, total waking time and waking time after sleep onset were decreased under DSIP treatment, but no significant differences were found in comparison to baseline or to double-blind placebo nights.
    1 context sentence
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, total sleep time was increased by DSIP.

    In plain wordsIn people with chronic insomnia, total sleep time was higher with DSIP.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    IncreaseTotal sleep time
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    Total sleep time and NREM sleep time were increased by the peptide.
    1 context sentence
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, NREM sleep time was increased by DSIP and was significantly higher than with placebo, but the same difference existed already at baseline.

    In plain wordsIn people with chronic insomnia, NREM sleep time was higher with DSIP than placebo, but the same gap was there before treatment.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    MixedNREM sleep time
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    Total sleep time and NREM sleep time were increased by the peptide.
    2 context sentences
    Summary · context
    For NREM sleep time and stage 2 sleep differences between DSIP and a placebo were significant, but the same differences existed already for the baseline values.
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, the DSIP increase in NREM sleep was related to more stage 2 sleep; the difference from placebo was significant but already present at baseline.

    In plain wordsIn people with chronic insomnia, stage 2 sleep was higher with DSIP than placebo, but the same gap was there before treatment.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    MixedStage 2 sleep
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    Their increase was related to increases in stage 2
    2 context sentences
    Summary · context
    For NREM sleep time and stage 2 sleep differences between DSIP and a placebo were significant, but the same differences existed already for the baseline values.
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, stage 1 sleep was not modified by DSIP.

    In plain wordsIn people with chronic insomnia, DSIP did not change stage 1 sleep.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeStage 1 sleep
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    while stage 1, slow wave sleep (stages 3 and 4) and rapid-eye-movement sleep were not modified
    1 context sentence
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, slow wave sleep was not modified by DSIP.

    In plain wordsIn people with chronic insomnia, DSIP did not change deep (slow wave) sleep.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeSlow wave sleep (stages 3 and 4)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    while stage 1, slow wave sleep (stages 3 and 4) and rapid-eye-movement sleep were not modified
    1 context sentence
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In chronic insomniacs, rapid-eye-movement sleep was not modified by DSIP.

    In plain wordsIn people with chronic insomnia, DSIP did not change REM sleep.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changeREM sleep
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    25 nmol/kg · intravenous · four nightsAs given in this study (human).

    Source sentences

    Summary
    while stage 1, slow wave sleep (stages 3 and 4) and rapid-eye-movement sleep were not modified
    1 context sentence
    Summary · context
    DSIP in a dose of 25 nmol/kg or a placebo was administered i.v. during four nights using a double-blind crossover design.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.